1801 — Innovent Biologics Share News
0.000.00%
Last trade - 00:00- HK$150.85bn
- HK$130.09bn
- CNY13.04bn
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis
Brief: Innovent Biologics Says Q3 2026 Product Revenue Exceeds RMB4.7 Bln
Takeda to seek Japan approval for gastric cancer drug next year
Advisory: Alert on Innovent Biologics Phase 3 study results withdrawn
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: US drugmakers turn to China for licensing deals
Brief: Innovent Biologics Says Jaypirca (Pirtrobrutinib) Approved In China For Cll/Sll Across All Lines Of Therapy
Brief: Jaypirca® (Pirtobrutinib) Approved In China For A New Indication In Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines Of Therapy
US weighs allowing most pharma licensing deals with China, sources say
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
China's drug regulator accepts Novo Nordisk's application for oral Wegovy (updated)
China's Jiangsu says it will support pharmaceutical firms' global M&A, licensing (updated)